151 related articles for article (PubMed ID: 18841028)
1. The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load.
Arase Y; Suzuki F; Sezaki H; Kawamura Y; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Yatsuji H; Hirakawa M; Kobayashi M; Ikeda K; Kumada H
Intervirology; 2008; 51(4):265-9. PubMed ID: 18841028
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of short-term interferon-beta therapy for type C cirrhotic patients with genotype 2a and low virus load.
Arase Y; Suzuki F; Sezaki H; Kawamura Y; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Yatsuji H; Kobayashi M; Saitoh S; Ikeda K; Kumada H
Intern Med; 2008; 47(12):1085-90. PubMed ID: 18552464
[TBL] [Abstract][Full Text] [Related]
3. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of interferon therapy in elderly patients with chronic hepatitis C.
Koyama R; Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2006; 49(3):121-6. PubMed ID: 16428887
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA.
Shiratori Y; Yokosuka O; Nakata R; Ihori M; Hirota K; Katamoto T; Unuma T; Okano K; Ikeda Y; Hirano M; Kawase T; Takano S; Matsumoto K; Ohashi Y; Omata M
Hepatology; 1999 May; 29(5):1573-80. PubMed ID: 10216145
[TBL] [Abstract][Full Text] [Related]
7. Management strategies using pharmacogenomics in patients with severe HCV-1b infection: a decision analysis.
Moriguchi H; Uemura T; Kobayashi M; Chung RT; Sato C
Hepatology; 2002 Jul; 36(1):177-85. PubMed ID: 12085363
[TBL] [Abstract][Full Text] [Related]
8. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety.
Russo MW; Goldsweig CD; Jacobson IM; Brown RS
Am J Gastroenterol; 2003 Jul; 98(7):1610-5. PubMed ID: 12873587
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2005 Apr; 75(4):550-8. PubMed ID: 15714492
[TBL] [Abstract][Full Text] [Related]
10. Association with 5'-untranslated region and response to interferon in chronic hepatitis C.
Katano Y; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
Hepatogastroenterology; 2007; 54(75):854-7. PubMed ID: 17591078
[TBL] [Abstract][Full Text] [Related]
11. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
Bressler BL; Guindi M; Tomlinson G; Heathcote J
Hepatology; 2003 Sep; 38(3):639-44. PubMed ID: 12939590
[TBL] [Abstract][Full Text] [Related]
12. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.
Maylin S; Martinot-Peignoux M; Moucari R; Boyer N; Ripault MP; Cazals-Hatem D; Giuily N; Castelnau C; Cardoso AC; Asselah T; Féray C; Nicolas-Chanoine MH; Bedossa P; Marcellin P
Gastroenterology; 2008 Sep; 135(3):821-9. PubMed ID: 18593587
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level.
Kawai S; Yokosuka O; Imazeki F; Saisho H; Mizuno C
J Med Virol; 2002 Nov; 68(3):343-51. PubMed ID: 12226820
[TBL] [Abstract][Full Text] [Related]
14. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
[TBL] [Abstract][Full Text] [Related]
15. [Structural analysis of the PKR-binding region of HCV 1b samples from patients with chronic hepatitis C and the correlation with IFN-sensitivity].
Gervain J; Czibula A; Simon J; Kalmár T
Orv Hetil; 2003 Jun; 144(24):1179-84. PubMed ID: 12866147
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of natural BALL-1 interferon-alpha treatment for patients with chronic hepatitis C and a possible enhancing effect of a twice-daily starting regimen with interferon-beta.
Ebinuma H; Saito H; Tada S; Nakamoto N; Kurita S; Kitamaura K; Horikawa H; Kumagai N; Tsuchimoto K; Ishii H; Hibi T;
Hepatogastroenterology; 2006; 53(67):94-9. PubMed ID: 16506384
[TBL] [Abstract][Full Text] [Related]
17. Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection?
Pellicano R; Puglisi G; Ciancio A; Balzola F; Saracco G; Ciccone G; Baldi I; Abate ML; Smedile A; Rizzetto M
J Med Virol; 2008 Apr; 80(4):628-31. PubMed ID: 18297716
[TBL] [Abstract][Full Text] [Related]
18. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.
Petta S; Cammà C; Di Marco V; Cabibi D; Ciminnisi S; Caldarella R; Licata A; Massenti MF; Marchesini G; Craxì A
Antivir Ther; 2009; 14(5):631-9. PubMed ID: 19704165
[TBL] [Abstract][Full Text] [Related]
19. Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
J Med Virol; 2007 Aug; 79(8):1095-102. PubMed ID: 17597485
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
Roche B; Sebagh M; Canfora ML; Antonini T; Roque-Afonso AM; Delvart V; Saliba F; Duclos-Vallee JC; Castaing D; Samuel D
Liver Transpl; 2008 Dec; 14(12):1766-77. PubMed ID: 19025933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
